Recombinant human erythropoietin reduces plasminogen activator inhibitor and ameliorates pro-infammatory responses following trauma

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 2, 2011, Pages 159-165

  Shiehmorteza, M ^a   Ahmadi, A ^b   Abdollahi, M ^c   Nayebpour, M ^a   Mohammadi, M ^d   Hamishehkar, H ^a   Najaf, A ^b   Pazoki, M ^b   Mojtahedzadeh, M ^a,b  

^a Faculty of Pharmacy   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Department of Pharmacology and Toxicology and Pharmaceutical Sciences Research Centre ^*  (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory; Anti oxidative; Recombinant human erythropoietin; SOFA; Trauma

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; INTERLEUKIN 1; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APACHE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INJURY; INTENSIVE CARE UNIT; OPEN STUDY; OXIDATIVE STRESS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 79958122732     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries, and risk factors in 1990 and projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
2. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med, 2004; 32:32-59.
3. Najaf A, Mojtahedzadeh M, Mahmoodpoor A, Aghamohammadi M, Ahmadi A, Nahreini S, Pazuki M, Khajavi MR, Abdollahi M. Effect of N-acetylcysteine on microalbuminuria in patients with acute respiratory distress syndrome. Arch Med Sci, 2009; 5:408-414.
4. Darlow BA, Buss H, McGill F, Fletcher L, Graham P, Winterbourn CC. Vitamin C supplementation in very preterm infants: a randomized controlled trial. Arch Dis Child Fetal Neonatal Ed, 2005; 90:117-122.
5. rion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preter infants. Cochrane Database Syst Rev, 2008; 149:9-15.
6. Mousavi, S., Mojtahedzadeh, M., Abdollahi, M. Place of iron chelators like desferrioxamine and deferasirox in management of hyperoxia-induced lung injury; a systematic review. 2010; 6:397-408.
7. P Katavetin, K Tungsanga, S Eiam-Ong and M Nangaku. Anti oxidative effects of erythropoietin. Kidney Int, 2007; 72:10-15.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med, 1985; 13:818-829.
9. Baker SP, O Neill B, Haddon W, Long WB. The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma, 1974; 14:187-196.
10. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units:results of a multicenter,prospective study. Crit Care Med,1998; 26:793-1800.
11. Marsden JT. Erythropoietin-measurement and clinical applications. Ann Clin Biochem, 2006; 43:97-104.
12. Soltan-Sharif MS, Mojtahedzadeh M, Najaf A, Khajavi MR, Rouini MR, Moradi M, Mohammadirad A, Abdollahi M. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: Evidence for underlying toxicological mechanisms. Human and Experimental Toxicology, 2007; 26:697-703.
13. Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB, Chopp M. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res, 2005; 1034:34-39.
14. Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A., Brines, M.L., Ghezzi, P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res, 2002; 952:128-134.
15. Mojtahedzadeh M, Rouini MR, Kajbaf F, Najaf A, Ansari G, Gholipour A, Mofd AR, Abdollahi M. Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for nonoccurrence of lactic acidosis and needing to parenteral metformin. Arch Med Sci, 2008; 4:74-81.
16. Monica Savioli, Massimo Cugno, Federico Polli, Paolo Taccone, Giacomo Bellani, Paolo Spanu, Antonio Pesenti, Gaetano Iapichino, Luciano Gattinoni, FRCP. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med, 2009; 37:424-431.
17. Hamishehkar H., Beigmohammadi M.T., Abdollahi M., Ahmadi A., Mahmoodpour A., Mirjalili M.R., Abrishami R., Khoshayand M.R., Eslami K., Kanani M., Baeeri M., Mojtahedzadeh M. Identification of enhanced cytokine generation following sepsis. Dream of magic bullet for mortality prediction and therapeutic evaluation. Daru, 2010; 18:155-162.
18. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo controlled trial. Lancet, 2003; 362:1255-1260.
19. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med, 2006; 355:2085-2098.
20. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int, 2001; 60:741-747.